FAF
BMRN icon

Första AP-fonden’s BioMarin Pharmaceuticals BMRN Stock Holding History

Första AP-fonden’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32,900
Closed -$1.78M – 547
2025
Q3 		$1.78M Sell
32,900
-300
-0.9% -$17.2K 0.01% 532
2025
Q2 		$1.83M Buy
33,200
+1,500
+5% +$88.3K 0.01% 532
2025
Q1 		$2.24M Sell
31,700
-4,700
-13% -$316K 0.02% 521
2024
Q4 		$2.39M Hold
36,400
– – 0.02% 531
2024
Q3 		$2.56M Buy
36,400
+3,400
+10% +$284K 0.02% 518
2024
Q2 		$2.72M Sell
33,000
-3,300
-9% -$275K 0.02% 478
2024
Q1 		$3.17M Buy
36,300
+4,000
+12% +$358K 0.03% 486
2023
Q4 		$3.11M Sell
32,300
-5,200
-14% -$460K 0.03% 466
2023
Q3 		$3.32M Buy
37,500
+700
+2% +$62.3K 0.04% 436
2023
Q2 		$3.19M Sell
36,800
-400
-1% -$37.6K 0.03% 460
2023
Q1 		$3.62M Sell
37,200
-6,000
-14% -$622K 0.04% 416
2022
Q4 		$4.47M Buy
43,200
+8,400
+24% +$789K 0.05% 393
2022
Q3 		$2.95M Buy
34,800
+10,100
+41% +$899K 0.04% 445
2022
Q2 		$2.05M Sell
24,700
-43,800
-64% -$3.49M 0.03% 504
2022
Q1 		$5.28M Buy
68,500
+57,200
+506% +$4.79M 0.06% 355
2021
Q4 		$998K Sell
11,300
-29,700
-72% -$2.45M 0.01% 526
2021
Q3 		$3.17M Sell
41,000
-32,900
-45% -$2.6M 0.04% 462
2021
Q2 		$6.17M Buy
73,900
+6,000
+9% +$476K 0.07% 334
2021
Q1 		$5.13M Buy
67,900
+34,200
+101% +$2.79M 0.07% 334
2020
Q4 		$2.96M Sell
33,700
-3,600
-10% -$285K 0.04% 432
2020
Q3 		$2.84M Buy
37,300
+9,300
+33% +$941K 0.06% 358
2020
Q2 		$3.45M Buy
28,000
+2,000
+8% +$199K 0.09% 243
2020
Q1 		$2.2M Buy
+26,000
New +$2.24M 0.08% 297

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Första AP-fonden's BMRN Position: Q4 2025 in Review

Första AP-fonden sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 32,900 shares — an estimated $1.78M sold.

Första AP-fonden first reported a position in BMRN in Q1 2020 and held it in 23 quarters. The position peaked at $6.17M in Q2 2021. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

  • Första AP-fonden reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Första AP-fonden sold 32,900 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $1.78M.
  • Första AP-fonden first reported a position in BioMarin Pharmaceuticals in Q1 2020 and held it in 23 quarters.
  • Första AP-fonden's BioMarin Pharmaceuticals position peaked at $6.17M in Q2 2021.
  • 540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Första AP-fonden's 13F filing for Q4 2025, filed 10 Feb 2026.